GRAL GRAIL, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Commercial-stage healthcare company focused on multi-cancer early detection (MCED) via Galleri blood-based screening test
• • New emphasis: 2026 PMA submission to FDA based on PATHFINDER 2 and NHS-Galleri Trial data; Medicare coverage pathway established under new federal law
• • Strategic shift: Scaling commercial operations with automated Galleri version launched late 2024; expanding international presence in Israel, Canada, South Korea
• • Notable metric: Over 475,000 Galleri tests sold by end of 2025, processing >800,000 total tests across clinical and commercial programs
• • Distinctive fact: NHS-Galleri Trial results in 140,000+ participants showed >20% stage 4 cancer diagnosis reduction despite missing primary endpoint, informing ongoing UK NHS evaluation

Risk Factors

• • Regulatory risk from Illumina Supply Agreement royalties commencing December 24, 2026, potentially increasing costs and impacting margins
• • U.S. market concentration with majority Galleri sales domestically, risk from limited broad reimbursement and pricing pressure from discounts and rebates
• • Operational risk from scaled platform leveraged by demand growth, but reduced investment in DAC and other product development beyond Galleri
• • Competitive risk from need to drive Galleri awareness post-positive study results, facing market competition in cancer screening tests
• • Financial risk from goodwill and intangible assets impairment review triggered by valuation changes since Illumina acquisition and pushdown accounting adjustments

Management Discussion & Analysis

• • Revenue not explicitly stated; commercial Galleri tests sold: 475,000 through 2025, including 185,000 in 2025
• • Net losses $408.4M (2025) vs $2.0B (2024) vs $1.5B (2023); Adjusted EBITDA $(320.6)M (2025) vs $(483.5)M (2024)
• • No segment revenue disclosed; primary business focus on Galleri multi-cancer early detection test commercialized in US
• • Equity raises: $311.3M net from $325M PIPE in Oct 2025; $107.5M net from ATM program shares in 2025; $110M equity investment from Samsung pending
• • Management expects continued operating losses due to R&D and commercialization investment; FDA PMA submission ongoing with trial results supporting product performance

What are the latest GRAL SEC filings in 2026?

GRAIL, Inc. (GRAL) has filed a 10-K annual report on March 12, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did GRAL file its most recent 10-K annual report?

GRAIL, Inc. (GRAL) filed its most recent 10-K annual report on March 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view GRAL 10-Q quarterly reports?

GRAIL, Inc. (GRAL)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every GRAL 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has GRAL filed recently?

GRAIL, Inc. (GRAL)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find GRAL insider trading activity (Form 4)?

SignalX aggregates every GRAL Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does GRAL file with the SEC?

GRAIL, Inc. (GRAL) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new GRAL filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for GRAIL, Inc. (GRAL).

What is GRAL's SEC CIK number?

GRAIL, Inc. (GRAL)'s SEC CIK (Central Index Key) number is 1699031. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1699031 to look up all GRAL filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find GRAL return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from GRAIL, Inc. (GRAL) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.